Compare ADMA Biologics Inc (ADMA) vs Godaddy Inc (GDDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Godaddy Inc — how do they compare? ADMA Biologics Inc trades at $9.92 (market cap $2.22B), while Godaddy Inc trades at $90.55 (market cap $11.49B). The key difference: Godaddy Inc is far larger — about 5.2× ADMA Biologics Inc's market cap. Which is the better fit depends on your goals.
| ADMA | GDDY | |
|---|---|---|
Market Cap | $2.22B | $11.49B |
Sector | Health | Technology |
52-Week High | $20.38 | $148.88 |
52-Week Low | $7.60 | $75.07 |
Enterprise Value | $2.29B | $14.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
GoDaddy (GDDY) trades at $91.49, up 0.46% today, with a neutral technical signal and strong fundamentals including a 17.83% net income margin and consistent earnings beats. Revenue growth is steady, projected at $5.1B for 2026, while recent news highlights legal investigations into potential securities violations, creating investor uncertainty.
The stock offers value with a P/E of 13.48 and a consensus price target of $112.13, but risks include ongoing legal scrutiny and high debt levels. Analyst sentiment remains bullish with 57% buy ratings, though technical indicators suggest near-term consolidation around key support at $90.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →
